| 09th week of 2011 patent applcation highlights part 64 |
| Patent application number | Title | Published |
|---|
| 20110053975 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES - The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly. | 2011-03-03 |
| 20110053976 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS - A compound of formula (I) | 2011-03-03 |
| 20110053977 | SMALL MOLECULE E2F INHIBITOR - A small molecular inhibitor of E2F (HLM006474) was identified using a computer-based virtual screen and the known crystal structure of the DNA bound E2F4/DP2 heterodimer. Treatment of multiple cell lines resulted in the loss of intracellular E2F4 DNA-binding activity. Overnight exposure to HLM006474 resulted in down regulation of total E2F4 protein as well as several known E2F targets. The effects of treatment on different cell lines included a reduction in cell proliferation and an increase in apoptosis. Apoptosis was induced in a manner distinct from cisplatin and doxorubicin. E2F4-null MEFs were less sensitive than wildtype counterparts to the apoptosis-inducing activity of the compound revealing its biological specificity. A375 cells were extremely sensitive to the apoptosis-inducing activity of the compound in two-dimensional culture and HLM006474 was a potent inhibitor of melanocytes proliferation and subsequent invasion in a three-dimensional tissue culture model system. | 2011-03-03 |
| 20110053978 | THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER - Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided. | 2011-03-03 |
| 20110053979 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS - This invention relates to pyridinamine methyl substituted piperidinyl derivatives I and their use as pharmaceuticals. | 2011-03-03 |
| 20110053980 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to indane-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the preparation of a medicament for the treatment of humans or animals. | 2011-03-03 |
| 20110053981 | Methods and Compositions Using Cholinesterase Inhibitors - The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine. | 2011-03-03 |
| 20110053982 | ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS - The present invention relates to compounds of the Formula (I), and pharmaceutically acceptable salts thereof, and their use in the treatment of FAAH-mediated diseases or condition. | 2011-03-03 |
| 20110053983 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY - Embodiments of the invention relate to (5R)-1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxamidine derivatives as cannabinoid-CB | 2011-03-03 |
| 20110053984 | NOVEL 4-BENZHYDRYLOXY-TETRAALKYL-PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R | 2011-03-03 |
| 20110053985 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2011-03-03 |
| 20110053986 | RESPIRATORY DISEASE TREATMENT - There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | 2011-03-03 |
| 20110053987 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME - Pegylated pyridinium and thiazolium compounds and methods of their use in medicine, research, industry, agriculture and recreational activities are disclosed. The present invention also provides methods of controlling microbial growth and infection. Additionally, the present invention provides methods of controlling microbial infestations relating to industrial and agricultural uses. The present invention can also be used to control insects. | 2011-03-03 |
| 20110053988 | Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke - A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 1.0 mg/ml. The composition used alone assists in reduction of the desire of a subject to smoke tobacco. It also reduces the nasal symptoms associated with administration of higher concentrations of nicotine to the nasal mucosa. | 2011-03-03 |
| 20110053989 | METHODS AND MATERIALS FOR TREATING ORTHOSTATIC HYPOTENSION OR POSTURAL TACHYCARDIA SYNDROME - This document provides methods and materials related to treating orthostatic hypotension and/or postural tachycardia syndrome. For example, methods and materials for using a composition containing 3,4-diaminopyridine, 4-aminopyridine, or both to treat patients with orthostatic hypotension, postural tachycardia syndrome, or both orthostatic hypotension and postural tachycardia syndrome are provided. | 2011-03-03 |
| 20110053990 | FATTY ACID NIACIN CONJUGATES AND THEIR USES - The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate. | 2011-03-03 |
| 20110053991 | Treatment of Histone Deacetylase Mediated Disorders - Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of histone deacetylase mediated disorders. | 2011-03-03 |
| 20110053992 | Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS) - Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders. | 2011-03-03 |
| 20110053993 | PRODRUGS OF DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS - Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity. | 2011-03-03 |
| 20110053994 | POTENT IMMUNOSUPPRESSIVE AGENTS, DERIVATIVES AND USES - Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drugs mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof. Moreover, the analogs, like pateamine A, are valuable molecular probes for evalutaion of eukaryotic translation initiation and as lead compounds for development of improved anticancer agents. | 2011-03-03 |
| 20110053995 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS - Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the benzenesulfonanilide class of compounds. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating cardiovascular, renal, and metabolic diseases, disorders, and conditions. Methods for identifying and using these agents that inhibit urea transporters are described herein. | 2011-03-03 |
| 20110053996 | Use of phenyltriazoles for controlling insects and spider mites by watering, droplet application or dip application or by treating seed - The present invention relates to the use of compounds of the formula (I) | 2011-03-03 |
| 20110053997 | Salts and Crystal Forms - The present invention relates to novel salts of the compound (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, polymorphs of the salts and methods of their preparation. | 2011-03-03 |
| 20110053998 | ETOMIDATE ANALOGUES WITH IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES - The invention is directed to compounds according to formula (I): where R | 2011-03-03 |
| 20110053999 | 4-METHYLPYRAZOLE FORMULATIONS FOR INHIBITING ETHANOL INTOLERANCE - Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity. | 2011-03-03 |
| 20110054000 | Crystalline Modifications of Pyraclostrobin - The present invention relates to novel crystalline modifications of pyraclostrobin, to processes for their preparation and to the use of the novel modifications for preparing crop protection compositions. | 2011-03-03 |
| 20110054001 | CHK1 SUPPRESSES A CASPASE-2 APOPTOTIC RESPONSE TO DNA DAMAGE THAT BYPASSES P53, BCL-2 AND CASPASE-3 - The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described. | 2011-03-03 |
| 20110054002 | ALKYL INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS - Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: | 2011-03-03 |
| 20110054003 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION - Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided. | 2011-03-03 |
| 20110054004 | METHOD FOR REDUCING SCARRING DURING WOUND HEALING USING ANTISENSE COMPOUNDS DIRECTED TO CTGF - This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring. | 2011-03-03 |
| 20110054005 | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same - The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.:
| 2011-03-03 |
| 20110054006 | REGULATION OF ONCOGENES BY MICRORNAS - Naturally occurring miRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions are administered to a subject prior to administration of a cytotoxic therapy in an amount effective to sensitize cells or tissues to be treated to the effects of the cytotoxic therapy. | 2011-03-03 |
| 20110054007 | COMPOSITIONS AND METHODS TO CONTROL INSECT PESTS - Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Coleopteran plant pest or a | 2011-03-03 |
| 20110054008 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 2011-03-03 |
| 20110054009 | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders - Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed. | 2011-03-03 |
| 20110054010 | Transcription Factor Decoys And Use Thereof - A pharmaceutical composition having a transcription factor decoy and a pharmaceutical acceptable carrier thereof is provided, wherein the transcription factor decoy is TCF decoy. A method for curing or preventing endotoxin-treated endothelial cells from apoptosis is provided. A method for treating or meliorating septic shock is also provided. The transcription factor decoy is effective on melioration of endothelial cell death after lipopolysaccharide challenge. Furthermore, the pharmaceutical composition is easy to be prepared, economic and has low immunogenicity. | 2011-03-03 |
| 20110054011 | RNA Antagonist Compounds for the Modulation of FABP4/AP2 - Oligonucleotides directed against the FABP4 gene are developed for modulating the expression of FABP4 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding FABP4. Methods of using these compounds for modulation of FABP4 expression and for the treatment of diseases associated with over expression of FABP4 are provided. Examples of such diseases are the metabolic syndrome, diabetes, atherosclerosis, and inflammatory states such as arthritis. The oligomer may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid (LNA) or a combination thereof. | 2011-03-03 |
| 20110054012 | Methods and Compositions for Increasing Gene Expression - The present invention provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a gene product in a cell by contacting the cell with a microRNA (miRNA) molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene. | 2011-03-03 |
| 20110054013 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula: | 2011-03-03 |
| 20110054014 | PRENYLFLAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds. | 2011-03-03 |
| 20110054015 | SOLID FORMS OF ORTATAXEL - The present invention relates to solid forms of 13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B when suspended and stirred in a mixture of ethanol and water for 4-8 hours. If the suspension is stirred for less than 4 hours, mixtures of Form B and Form A are obtained. Form B or mixtures of Forms A and B can also be obtained dissolving Ortataxel in a protic organic solvent, followed by addition of water. | 2011-03-03 |
| 20110054016 | METHOD FOR MODULATING CLAUDIN MEDIATED FUNCTIONS - Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above. | 2011-03-03 |
| 20110054017 | SUBSTITUTED FURANS AND THEIR USE - The present application relates to novel substituted furan derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases. | 2011-03-03 |
| 20110054018 | Inotilone derivatives as coherent biological response modifier (cBMR) - Optimal compositions of derivatives of 5-methyl-3(2H)-furanone compounds and phenylpropanoid polyketides related to inotilone, that exert biological response modification in health and disease, and their method of preparation, are disclosed. Methods of treating degenerative conditions stemming from over-expression of inducible nitric oxide synthase (iNOS) using these compositions are also disclosed. | 2011-03-03 |
| 20110054019 | Cancer Starvation Therapy - The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction. | 2011-03-03 |
| 20110054020 | NAPTHYLENE INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new napthylene inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof | 2011-03-03 |
| 20110054021 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 2011-03-03 |
| 20110054022 | Method for Preparing Dicaffeoylquinic Acids and Use Thereof in Combating Aphids - Method for preparing 3,5-dicaffeoylquinic acid and certain derivatives thereof, and use thereof in the preparation of plant-protection products. Method for combating aphids using 3,5-dicaffeoylquinic acid and certain derivatives thereof. | 2011-03-03 |
| 20110054023 | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses - The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a cancer cell, tissue or tumor. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a tumor, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods. | 2011-03-03 |
| 20110054024 | Use of hop acids in fuel ethanol production - Six hop acids are common to hops and beer: alpha acid, beta acids, isoalpha acids, rho-isoalpha acids, tetrahydro-isoalpha acids, and hexahydro-isoalpha acids. The six hop acids were tested to determine which were the most effective in inhibiting the growth of bacteria common to fuel ethanol production. The bacteria used in the tests were | 2011-03-03 |
| 20110054025 | USE OF A PENTACYCLIC TRITERPENE IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Oleanolic acid (3β-hiydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene occurring in a large number of medicinal plants. The present invention is directed to the pharmacological application of the oleanolic acid, alone or in combination with other substances, in the treatment or prophylaxis of neurodegenerative diseases such as multiple sclerosis. The inventors have found that oleanolic acid, intraperitoneally administered once daily, reduces significantly the immuno-inflammatory and neurological symptoms associated with the experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, delaying the onset and reducing the progression of the disease. | 2011-03-03 |
| 20110054026 | ANTIMICROBIAL COMPOSITION AND USE - Antimicrobial compositions are provided comprising a pharmaceutically acceptable organic acid and a pharmaceutically acceptable surfactant. This synergistic combination allows compositions to be formulated at low concentrations that have efficacy in reducing bacterial counts by greater than 3 log within 5 minutes of contact while preserving the organoleptic properties of treated foods, including fresh produce. As shown in FIG. | 2011-03-03 |
| 20110054027 | PRODUCTION OF BIOFUEL FROM TISSUE CULTURE SOURCES - The present invention provides a method for the production of at least one fatty acid and/or oil from a plant cell suspension culture, the method comprising (i) maintaining a cell suspension culture of oil-producing plant cells under conditions such that the cultured cells synthesise and secrete at least one fatty acid and/or oil into the cell suspension culture medium; and (ii) extracting the thus secreted at least one fatty acid and/or oil from the cell suspension culture medium. | 2011-03-03 |
| 20110054028 | SUPPLEMENT FOR REDUCING HIV TRANSMISSION AND METHOD THEREOF - There is an urgent need for a method to reduce the risk of mother-to-child transmission (MTCT) of HIV during breastfeeding in HIV pandemic regions. The present invention provides a supplement for reducing the chance of transmitting HIV during MTCT and method thereof. The supplement comprising arachidonic acid (AA) alone, or a mixture of AA and DHA at safe intake doses. The supplement is provided to either the breastfeeding mothers or the babies to maintain cell membrane potential polarization through activation of the background potassium channels, thereby reducing the risk of HIV transmission. | 2011-03-03 |
| 20110054029 | WATER-SOLUBLE DIETARY FATTY ACIDS - Water-soluble dietary fatty acid formulations, solutions, and methods for increasing the water solubility and/or bioavailability of dietary fatty acids, as well as methods for treating various diseases are disclosed. | 2011-03-03 |
| 20110054030 | USE OF EICOSAPENTAENOIC ACID AND/OR DOCOSAHEXAHENOIC ACID IN WOMEN WITH ENDOMETRIOSIS - The present invention pertains to the use of essential fatty acids for the preparation of a food composition for treating in particular post-surgical pain and/or pain due to a post-surgical relapse in women having undergone an operation for endometriosis. Said essential fatty acids are preferably selected from the group consisting of long-chain polyunsaturated fatty acids of the omega-3 series, and in particular from the group comprising EPA and/or DHA. | 2011-03-03 |
| 20110054031 | Ophthalmic NSAIDS as Adjuvants - The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion. | 2011-03-03 |
| 20110054032 | DIOXOANTHRACENE SULPHONATE DERIVATIVES - Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R | 2011-03-03 |
| 20110054033 | METHODS OF USING ABSCISIC ACID FOR AMELIORATING HYPERTENSION AND VASCULAR INFLAMMATION - Methods and compositions for treating or preventing hypertension or vascular inflammation are described. These methods of the invention involve the administration of abscisic acid (ABA) to subjects in need thereof. | 2011-03-03 |
| 20110054034 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS - A method of treating a disease or condition in a warm blooded mammal which disease or condition is suspected to be associated with a microbial infection, comprising: administering an antimicrobial effective amount of a carboxylic acid amide, its isomers or salts thereof, to a subject who is suspected to be infected with a microbe. In one embodiment, the carboxylic acid amide is trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxyphenyl)amide. | 2011-03-03 |
| 20110054035 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 2011-03-03 |
| 20110054036 | COMPOSITION AND METHOD FOR IRRIGATION OF A PREPARED DENTAL ROOT CANAL - Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection. | 2011-03-03 |
| 20110054037 | BIS-AROMATIC ANTICANCER AGENTS - Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described. | 2011-03-03 |
| 20110054038 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE - The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released. | 2011-03-03 |
| 20110054039 | USE OF ALKYL SULFATES OR SULFONATES AGAINST PROPIONIBACTERIUM ACNES - An alkyl sulphate or sulphonate having a carbon chain length of 11 or greater, for use in the treatment of a condition which is caused by, transmitted by and/or exacerbated by propionibacterial activity, in particular acne. | 2011-03-03 |
| 20110054040 | Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy - This invention relates to a Bicyclic triterpenoid Iripallidal as a novel anti-glioma and anti neoplastic agent, having the composition [(−)(6R,10S,11S,18R,22S)-26 Hydroxy-22-α methylcyloirid-16-enal NSC 631939], wherein it binds to Ras GRP3, a phorbol ester receptor that links DAG/phorbolester signaling with Ras activation and induces phosphorylation of ER K1/2 in a Ras dependent manner, reducing proliferation of cancer cell lines to the extent of 50-70%. | 2011-03-03 |
| 20110054041 | Oil-In-Water Type Cosmetic Emulsion - The invention provides an oil-in-water type cosmetic emulsion which can be applied to the skin without stickiness, and impart resilient and supple feel to the skin, while having good stability without causing viscosity decrease or separation even during a long-term storage. The oil-in-water type cosmetic emulsion comprises (a) a higher alcohol having 14 to 22 carbon atoms, (b) a hydrophilic polyoxyethylene alkyl ether, and (c) a glycerin monoalkyl ether, wherein alkyl moieties in (b) and (c) are linear saturated alkyl chains, and molar concentrations of (a) to (c) satisfy a relation [(b)+(c)]/(a)=0.1 to 1.0, and preferably satisfy a relation [(a)+(c)]/(b)=3 to 20. | 2011-03-03 |
| 20110054042 | Polymer compositions - A composition contains an incompletely hydrated water soluble polymer suspended in a liquid medium. | 2011-03-03 |
| 20110054043 | FILM COMPOSITION - A film composition comprising (i) a resin obtained by copolymerizing polyvinyl alcohol and at least one or more polymerizable vinyl monomers; and (ii) a drug or a food component. | 2011-03-03 |
| 20110054044 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF SYNTHETIC HYDROCARBON COMPOUNDS - A process and system for producing hydrocarbon compounds or fuels that recycle products of hydrocarbon compound combustion—carbon dioxide or carbon monoxide, or both, and water. The energy for recycling is electricity derived from preferably not fossil based fuels, like from nuclear fuels or from renewable energy. The process comprises electrolysing water, and then using hydrogen to reduce externally supplied carbon dioxide to carbon monoxide, then using so produced carbon monoxide together with any externally supplied carbon monoxide and hydrogen in Fischer-Tropsch reactors, with upstream upgrading to desired specification fuels—for example, gasoline, jet fuel, kerosene, diesel fuel, and others. Energy released in some of these processes is used by other processes. Using adiabatic temperature changes and isothermal pressure changes for gas processing and separation, large amounts of required energy are internally recycled using electric and heat distribution lines. Phase conversion of working fluid is used in heat distribution lines for increased energy efficiency. The resulting use of electric energy is less than 1.4 times the amount of the high heating value of combustion of so produced hydrocarbon compounds when carbon dioxide is converted to carbon monoxide in the invention, and less than 0.84 when carbon monoxide is the source. | 2011-03-03 |
| 20110054045 | CONVERSION OF CARBON DIOXIDE TO METHANOL USING BI-REFORMING OF METHANE OR NATURAL GAS - The invention provides for \ a method of forming methanol by combining a mixture of methane, water and carbon dioxide under reaction conditions sufficient to form a mixture of hydrogen and carbon monoxide. Hydrogen and carbon monoxide are reacted under conditions sufficient to form methanol. The molar ratio of hydrogen to carbon monoxide is at least two moles of hydrogen to one mole of carbon monoxide and the overall molar ratio between methane, water and carbon dioxide is about 3:2:1. Methane, carbon dioxide and water are bi-reformed over a catalyst. The catalyst includes a single metal, a metal oxide, a mixed catalyst of a metal and a metal oxide or a mixed catalyst of at least two metal oxides. | 2011-03-03 |
| 20110054046 | METHOD OF COMBINING EXISTING CHEMICAL PROCESSES TO PRODUCE HYDROCARBON FUELS - A method for producing hydrocarbon fuels from environmentally friendly non-petroleum based sources using existing chemical reactions is disclosed. In this method, air is passed through a reactor containing amine and carbon dioxide mixture to produce carbon dioxide. The reactor containing amine and carbon dioxide mixture, a Sabatier reactor, a partial oxidation reactor and a Fischer-Tropsch reactor are in thermal contact with each other. The exothermic reactions, the Sabatier reaction and partial oxidation reaction drive the endothermic Fischer-Tropsch reaction. The Fischer Tropsch reaction occurs under a high temperature generated from the heat liberated by the Sabatier reaction and partial oxidation reaction. The heat from the exothermic reactions can also be used to release carbon dioxide from the amine-carbon dioxide mixture. The resulting hydrocarbon fuel products are separated from the Fischer Tropsch reactor and sold. | 2011-03-03 |
| 20110054047 | SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF SYNTHETIC HYDROCARBON COMPOUNDS - A process and system for producing hydrocarbon compounds or fuels that recycle products of hydrocarbon compound combustion—carbon dioxide or carbon monoxide, or both, and water. The energy for recycling is electricity derived from preferably not fossil based fuels, like from nuclear fuels or from renewable energy. The process comprises electrolysing water, and then using hydrogen to reduce externally supplied carbon dioxide to carbon monoxide, then using so produced carbon monoxide together with any externally supplied carbon monoxide and hydrogen in Fischer-Tropsch reactors, with upstream upgrading to desired specification fuels—for example, gasoline, jet fuel, kerosene, diesel fuel, and others. Energy released in some of these processes is used by other processes. Using adiabatic temperature changes and isothermal pressure changes for gas processing and separation, large amounts of required energy are internally recycled using electric and heat distribution lines. Phase conversion of working fluid is used in heat distribution lines for increased energy efficiency. The resulting use of electric energy is less than 1.4 times the amount of the high heating value of combustion of so produced hydrocarbon compounds when carbon dioxide is converted to carbon monoxide in the invention, and less than 0.84 when carbon monoxide is the source. | 2011-03-03 |
| 20110054048 | COBALT CATALYSTS - Catalysts comprising cobalt on a titania support are produced by mixing together particles of a solid titania support and an aqueous solution of cobalt ammine carbonate, and heating to an elevated temperature sufficient to effect decomposition of the cobalt ammine carbonate and precipitation of a cobalt species onto said support. The catalysts are useful in hydrogenation and Fischer-Tropsch reactions. | 2011-03-03 |
| 20110054049 | OXIDATION-REDUCTION ACTIVE MASS AND CHEMICAL-LOOPING COMBUSTION METHOD - The invention relates to a method for chemical-looping redox combustion on an active mass including a binder, in form of a fluidized-bed catalytic cracking catalyst containing silica and alumina, and a metal oxide active phase. The active mass is obtained by impregnating metal salts on a new or used catalytic cracking catalyst. Advantageously, the invention applies to the sphere of CO | 2011-03-03 |
| 20110054050 | ION EXCHANGE MEMBRANE HAVING LAMELLAR MORPHOLOGY AND PROCESS OF MAKING THE SAME - An ion exchange membrane is prepared from a block copolymer comprising a hydrophobic polymer segment and a polar polymer segment. The ion exchange membrane is formed by placing a film layer in steam, water or an electric field at a temperature greater than about 40° C. for sufficient amount of time to develop a bicontinuous morphology. The ion exchange membrane is also formed from a film layer comprising a block copolymer and a solvent. The film layer is placed in an electric field at an elevated temperature and dried therein. The film layer is thereby converted into an ion exchange membrane with bicontinuous morphology. The ion exchange membrane prepared according to these processes exhibits improved mechanical and electrochemical properties. | 2011-03-03 |
| 20110054051 | PROCESSES FOR RECOVERING RUBBER FROM NATURAL RUBBER LATEX - Processes for recovering natural rubber from an aqueous natural rubber latex that contains extractables and one or more additives and that is essentially free of lignocellulosic plant material are described. Natural rubber in the latex is separated from the water. Preferably, the amount of non-rubber extractables in the natural rubber is reduced by one or more extraction steps yielding a dried natural rubber. | 2011-03-03 |
| 20110054052 | POLYURETHANE FOAM COMPOSITION AND POLYURETHANE FOAM PREPARED USING SAME - A polyurethane foam composition that includes polyol, isocyanate, a catalyst, a surfactant, a physical blowing agent, a chemical blowing agent, a nucleating agent and a silsesquioxane compound is provided. | 2011-03-03 |
| 20110054053 | ADDITIVES IN GYPSUM PANELS AND ADJUSTING THEIR PROPORTIONS - A panel is provided that includes stucco, water and a dispersant component having dispersing properties and comprising a comb-branched polymer with polyether side chains, naphthalene sulfonate-formaldehyde condensate or melamine sulfonate-formaldehyde condensate. A polycondensation component is also included in the slurry that includes three repeating units. A method of making the gypsum panel includes combining stucco, water and a first dosage of a first dispersant to form a slurry, the first. A second dosage of a second dispersant is added to the slurry. Properties of the gypsum slurry are tested and it is formed into a product. The product sets and properties of the product are identified. The first dosage or the second dosage is changed based on the properties of the slurry or product. | 2011-03-03 |
| 20110054054 | HYDRAZINE-MODIFIED MATRICES AND USE THEREOF IN METHODS FOR ISOLATING BIOMOLECULES - The invention relates to novel functionalized matrices or matrix materials comprising structures of general formula Carrier-Linker-Spacer-NR | 2011-03-03 |
| 20110054055 | LOW-PHOSPHORUS LAMINATION ADDITIVES HAVING LOW EMISSION, IMPROVED INITIAL ADHESION AND IMPROVED HYDROLYSIS STABILITY - A composition is provided which is suitable for producing polyurethane systems appropriate for hot adhesive bonding. The composition includes from 0.1 to 20% by mass of an additive mixture comprising at least one organic phosphorus compound either alone or in combination with a crosslinker or extender. | 2011-03-03 |
| 20110054056 | THERMOSET POLYURETHANES - Thermoset polyurethanes comprising a cis, trans-1,3- and -1,4-cyclohexanedimethylether moiety. Adducts of epoxy resins comprising a cis, trans-1,3- and -1,4-cyclohexanedimethylether moiety are used to react with a polyisocyanate to produce the thermoset polyurethanes. | 2011-03-03 |
| 20110054057 | Polyurethane polishing pad - The polishing pad is suitable for planarizing at least one of semiconductor, optical and magnetic substrates. The polishing pad includes a cast polyurethane polymeric material formed with an isocyanate-terminated reaction product formed from a prepolymer reaction of a prepolymer polyol and a polyfunctional isocyanate. The isocyanate-terminated reaction product has 4.5 to 8.7 weight percent unreacted NCO; and the isocyanate-terminated reaction product is cured with a curative agent selected from the group comprising curative polyamines, curative polyols, curative alcoholamines and mixtures thereof. The polishing pad contains at least 0.1 volume percent filler or porosity. | 2011-03-03 |
| 20110054058 | Emulsified polyol and resultant foam therefrom - An improved polyol, having a first component combined with a second component, one of the first and second components being hydrophobic and one of the first and second components being hydrophillic, at least one of the components being in a stable encapsulation or being in a stable emulsion, desirably formed of calcium carbonate and silicon dioxide. | 2011-03-03 |
| 20110054059 | METHODS FOR PRODUCING POLYOLS AND POLYURETHANES - Methods for producing a polyols and polyurethanes are described. The polyols described herein can be produced directly from crude glycerin or through liquefaction of lignocellulosic biomass using a solvent comprising crude glycerin. The polyols produced in accordance with certain aspects may be derived from a significant proportion of renewable resources. | 2011-03-03 |
| 20110054060 | NATURAL OIL BASED POLYOL BLENDS - A natural oil based polyol blend is provided. The blend includes a first natural oil based polyol comprising is the reaction product of a first monomer and a first initiator, and where the first monomer is derived from at least one first fatty acid methyl ester. The blend also includes a second natural oil based polyol comprising the reaction product of a second monomer and a second initiator. The second monomer is derived from at least one second fatty acid methyl ester, and at least one of the second monomer and the second initiator is different from the first monomer and the first initiator, respectively. The natural oil based polyol blend may be reacted with an isocyanate to form a foam. | 2011-03-03 |
| 20110054061 | SEALANT FOR ONE DROP FILL PROCESS CONTAINING PHOTO-CURABLE RESIN AND HEAT-CURABLE RESIN - A sealant for a one drop fill process of the invention contains the following components (1), (2), (3), and (4): (1) a curing agent composed of a reaction product produced by reacting an acid compound and a polyamine containing, within its molecule, at least one active hydrogen and at least two nitrogen atoms; (2) a heat-curable resin; (3) an acylphosphine-based photoinitiator; and (4) a photo-curable resin. A heat-curable resin containing a bisphenol A propylene oxide-modified epoxy resin is preferably used as the heat-curable resin (2), and a photo-curable resin containing a bisphenol A acrylate-modified resin is preferably used as the photo-curable resin (4). | 2011-03-03 |
| 20110054062 | UV Pressure-Sensitive Adhesive for Stickers and Labels - A UV pressure-sensitive adhesive is described. In one aspect of the invention, the adhesive comprises a UV rosin-monomer blend, an acrylated urethane polyol, a TPDGA tripropylene glycol, a UV flexo photoinitiator, a nonionic wetting agent and molecular defoamer, and a slip additive and deaerator. In another aspect of the invention, the adhesive comprises a UV low odor rosin varnish, an acrylated urethane polyol, a TPDGA tripropylene glycol diacrylate, a multifunctional triacrylate monomer, a UV low odor photoinitiator, a nonionic wetting agent and molecular defoamer, a slip additive and deaerator, and a fragrance. | 2011-03-03 |
| 20110054063 | ORGANOSILICON COMPOUNDS WHICH HAVE OXETANYL GROUPS, AND A METHOD FOR THE PRODUCTION AND CURABLE COMPOSITIONS OF THE SAME - The object of the present invention is to provide an organosilicon compound having an oxetanyl group, which has a high proportion of an inorganic part in the structure, which, after production thereof, is stable with no gelling, and which has excellent storage stability when it is formed into a composition, and a production method thereof and a curable composition. The organosilicon compound is a compound having an oxetanyl group obtained by a method including a process in which a silicon compound A represented by the formula (1) and a silicon compound B having four siloxane bond-forming groups are subjected to hydrolysis and condensation at a ratio of 0.3 to 2.8 mol of silicon compound B based on 1 mol of silicon compound A. | 2011-03-03 |
| 20110054064 | Hydrogel Compositions and Methods of Preparation Thereof - A block copolymer includes a hydrophobic block and a hydrophilic block, wherein the hydrophobic block and the hydrophilic block include repeating units derived from ring opening polymerization of one or more cyclic carbonate monomers. The one or more cyclic carbonate monomers are independently selected from compounds of the general formula (II): | 2011-03-03 |
| 20110054065 | MEDICAL INSTRUMENT, MEDICAL MATERIAL, AND METHOD FOR PRODUCTION OF THE MEDICAL INSTRUMENT AND MEDICAL MATERIAL - Disclosed are a medical instrument and a medical material each comprising an aliphatic polyester resin composition, which are hardly reduced in strength and impact resistance upon the sterilization by ionizing radiation or have excellent shape-retaining properties after a heat treatment. Specifically, a medical instrument and a medical material both sterilized by ionizing radiation are provided, each of which contains a biodegradable resin and a polycarbodiimide compound in an amount of 0.1 to 10% by weight on the resin. The biodegradable resin is polybutylene succinate, a copolymer of polybutylene succinate, or a mixture of polybutylene succinate and a copolymer of polybutylene succinate with polylactic acid or poly(3-hydroxyalkanoate). A method of producing such medical instrument and medical material is also provided. | 2011-03-03 |
| 20110054066 | USE OF POLYMERIZABLE MACROCYCLIC POLYETHERS AND MACROCYCLIC HETEROANALOGOUS POLYETHERS IN DENTAL MATERIALS - Radically polymerizable macrocyclic polyethers or macrocyclic heteroanalogous polyethers, preferably crown ethers, heteroanalogous crown ethers and cryptands for use in dental materials is disclosed. | 2011-03-03 |
| 20110054067 | Radiation-Induced Thickening for Set-On-Command Sealant Compositions - The present invention includes compositions relating to the setting of fluids or slurries in a wellbore. In one embodiment, a sealant composition having a fluid component and a polymeric additive component can be subjected to ionizing radiation. The ionizing radiation can cause bonding between polymeric additive components and create a polymer matrix within the sealant composition that increases the mechanical strength of the sealant composition. | 2011-03-03 |
| 20110054068 | Radiation-Induced Triggering for Set-On-Command Compositions - The present invention relates to compositions useful for isolating a portion of a wellbore. In one embodiment, a composition includes a sealant composition containing a wellbore treatment fluid and a set modifier component. The sealant composition can be placed into the wellbore and subjected to ionizing radiation that alters the set modifier component, triggering the setting of the sealant composition. | 2011-03-03 |
| 20110054069 | RUBBER COMPOSITION HAVING IMPROVED CRACK RESISTANCE - Disclosed is a rubber composition which comprises: (a) a first polymer, (b) a second polymer that is different from said first polymer, (c) a filler, (d) a first low molecular weight polymer comprising a block A and a block B, wherein said block A comprises a majority of the same type of mer units that make up a majority of the first polymer and block B comprises a majority of the same type of mer units that make up a majority of the second polymer, and (e) a second low molecular weight polymer comprising at least one functional group, wherein said first and second low molecular weight polymers have number average molecular weights of about 5,000 to about 100,000. Also disclosed is a method of mixing the rubber composition. | 2011-03-03 |
| 20110054070 | Self-Reparing Concrete Having Polyurethane Polymer Micro-Capsules and Method for Fabricating the Same - A self-repairing concrete includes polyurethane polymer micro-capsules, in which the polyurethane polymer micro-capsules are mixed for a fixed function of micro-cracks. The quality mixture ratio is: concrete/micro capsules/water=100:1-15:15-50. The manufacturing method is weighing a full amount of water in a container, adding polyurethane polymer micro-capsules, stirring, until fully dispersed microcapsules; pouring the water into the mixing container, adding the corresponding quality of cement; stirring; adding sand and gravel filling materials, conducting worksite watering, ⅓ volume for each time, vibrating, and air exhausting; until the slurry filling mold. | 2011-03-03 |
| 20110054071 | METHOD AND DEVICE FOR THE CONTINUOUS PRODUCTION OF POLYMERS BY RADICAL POLYMERIZATION - The present invention relates to a method for the continuous production of a polymer by radical polymerization, wherein at least three materials are mixed with microstructures in one or more mixers and are then polymerized in at least one reaction zone. | 2011-03-03 |
| 20110054072 | WHITE HEAT-CURABLE SILICONE/EPOXY HYBRID RESIN COMPOSITION FOR OPTOELECTRONIC USE, MAKING METHOD, PREMOLDED PACKAGE, AND LED DEVICE - A white heat-curable silicone/epoxy hybrid resin composition is provided comprising (A) a heat-curable silicone resin, (B) a triazine derived epoxy resin composition, (C) a white pigment, (D) an inorganic filler, and (E) an antioxidant. Antioxidant (E) is a phosphite compound having formula: P(OR | 2011-03-03 |
| 20110054073 | CURABLE COMPOSITION AND USE THEREOF - This invention relates to a curable composition comprising one or more of organic metal compounds as resin bleed-out controller and its application in semiconductor packages. Particularly, the organic metal compound is an organic titanate. In some embodiments, the organic titanates include, but are not limited to tetraalkyl titanates and titanate chelates. The composition shows excellent performance in bleeding-out control and thus can reduce the occurrence of failure, such as die top delamination, in semiconductor packages. | 2011-03-03 |
| 20110054074 | ADHESIVE - The present invention relates to an adhesive comprising at least one matrix material and core/shell particles comprising cores having a diameter in the range from 1 nm to 1 μm with a shell comprising oligomers and/or polymers, and to a process for the preparation thereof. | 2011-03-03 |
